See more : ProstaLund AB (publ) (PLUN.ST) Income Statement Analysis – Financial Results
Complete financial analysis of biote Corp. (BTMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of biote Corp., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Arcoma AB (ARCOMA.ST) Income Statement Analysis – Financial Results
- Oil Refineries Ltd. (OILRF) Income Statement Analysis – Financial Results
- Kingman Minerals Ltd. (KGS.V) Income Statement Analysis – Financial Results
- Versity (MLVSY.PA) Income Statement Analysis – Financial Results
- NAHL Group Plc (NAH.L) Income Statement Analysis – Financial Results
biote Corp. (BTMD)
About biote Corp.
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 185.36M | 164.96M | 139.40M | 116.57M | 109.98M |
| Cost of Revenue | 57.88M | 54.58M | 48.82M | 44.93M | 43.57M |
| Gross Profit | 127.48M | 110.38M | 90.58M | 71.64M | 66.41M |
| Gross Profit Ratio | 68.78% | 66.92% | 64.98% | 61.46% | 60.39% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 165.50M | 49.05M | 33.02M | 32.03M |
| Selling & Marketing | 0.00 | 4.63M | 4.91M | 4.41M | 7.26M |
| SG&A | 98.83M | 170.13M | 53.96M | 37.43M | 39.29M |
| Other Expenses | 0.00 | 974.00K | 2.06M | 2.43M | 3.59M |
| Operating Expenses | 98.83M | 171.10M | 56.02M | 39.86M | 42.88M |
| Cost & Expenses | 156.70M | 225.68M | 104.84M | 84.79M | 86.45M |
| Interest Income | 0.00 | 5.09M | 1.67M | 2.43M | 2.08M |
| Interest Expense | 6.36M | 5.09M | 1.67M | 2.43M | 2.08M |
| Depreciation & Amortization | 2.99M | 2.44M | 1.40M | 1.14M | 832.00K |
| EBITDA | 9.23M | 9.24M | 35.98M | 32.91M | 24.29M |
| EBITDA Ratio | 4.98% | -34.83% | 24.81% | 28.24% | 22.09% |
| Operating Income | 28.66M | -60.72M | 34.56M | 31.78M | 23.53M |
| Operating Income Ratio | 15.46% | -36.81% | 24.79% | 27.26% | 21.39% |
| Total Other Income/Expenses | -28.78M | 62.43M | -1.66M | -2.43M | -2.15M |
| Income Before Tax | -123.00K | 1.71M | 32.91M | 29.35M | 21.38M |
| Income Before Tax Ratio | -0.07% | 1.04% | 23.61% | 25.18% | 19.44% |
| Income Tax Expense | 2.68M | 388.00K | 286.00K | 189.00K | 93.00K |
| Net Income | 3.32M | 1.32M | 32.62M | 29.16M | 21.29M |
| Net Income Ratio | 1.79% | 0.80% | 23.40% | 25.02% | 19.36% |
| EPS | 0.13 | 0.16 | -0.87 | 3.85 | 2.81 |
| EPS Diluted | 0.13 | 0.16 | -0.87 | 3.85 | 2.81 |
| Weighted Avg Shares Out | 25.71M | 8.06M | 7.57M | 7.57M | 7.57M |
| Weighted Avg Shares Out (Dil) | 25.71M | 8.06M | 7.57M | 7.57M | 7.57M |
Does biote Corp. (BTMD) Have the Potential to Rally 43.89% as Wall Street Analysts Expect?
The mean of analysts' price targets for biote Corp. (BTMD) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
Are Investors Undervaluing biote Corp. (BTMD) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
biote Corp. (BTMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for biote Corp. (BTMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for...
Wall Street Analysts Predict a 76.99% Upside in biote Corp. (BTMD): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 77% in biote Corp. (BTMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
Is biote Corp. (BTMD) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
biote Corp. (BTMD) Q3 2024 Earnings Call Transcript
biote Corp. (NASDAQ:BTMD ) Q3 2024 Earnings Call November 12, 2024 5:00 PM ET Company Participants Szymon Serowiecki - Investor Relations Terry Weber - Chief Executive Officer Bob Peterson - Chief Financial Officer Conference Call Participants Jonna Kim - Cowen...
Biote Corp. (BTMD) Beats Q3 Earnings Estimates
Biote Corp. (BTMD) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.11 per share a year ago.
Wall Street Analysts See an 88.04% Upside in biote Corp. (BTMD): Can the Stock Really Move This High?
The consensus price target hints at an 88% upside potential for biote Corp. (BTMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...
Is biote Corp. (BTMD) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
biote Corp. (BTMD) Q2 2024 Earnings Call Transcript
biote Corp. (NASDAQ:BTMD ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Szymon Serowiecki – Investor Relations Terry Weber – Chief Executive Officer Bob Peterson – Chief Financial Officer Conference Call Participants Les Sulewski –...
Source: https://incomestatements.info
Category: Stock Reports